Analyst Edward White of H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), retaining the price target of $6.00.
Edward White’s rating is based on the promising clinical progress of SAB Biotherapeutics’ SAB-142, which has shown positive Phase 1 results in healthy volunteers. The drug, designed to delay the onset or progression of type 1 diabetes, demonstrated a clinically validated multi-target mechanism of action with sustained immunomodulation and a favorable safety profile. Unlike other treatments, SAB-142 did not cause sustained lymphodepletion or adverse drug reactions, which positions it as a potentially superior therapeutic option.
Furthermore, the anticipated initiation of a Phase 2b study in mid-2025, targeting new-onset stage 3 type 1 diabetes, adds to the positive outlook. The study aims to explore a competitive dosing regimen and is expected to yield interim data by mid-2026. With a forecasted launch in 2029 and projected sales growth, SAB-142 represents a significant opportunity for SAB Biotherapeutics, justifying the Buy rating.